查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1986453

肺动脉高压治疗市场报告：按药物类别、给药途径、最终用户和地区划分（2026-2034 年）

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球肺动脉高压（PAH）治疗市场规模达84亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到121亿美元，2026年至2034年的复合年增长率（CAGR）为4.05%。该市场正经历显着成长，主要得益于标靶治疗的进步、PAH盛行率的上升以及公众意识的提高。不断扩大的研发投入也为全球市场带来了更光明的前景。

肺动脉高压治疗市场趋势：

扩大联合治疗的应用

为了提高肺动脉高压 (PAH) 的治疗效果，医生们越来越多地采用联合治疗。透过合併使用不同治疗类别的药物，他们能够针对治疗 PAH 涉及的多个生物学路径。这种多管齐下的方法有助于更有效地控制症状、延缓疾病进展并改善患者的整体预后。此外，联合治疗还可以降低单一药物的剂量，从而可能减少副作用并提高患者的依从性。随着临床证据支持其有效性，联合治疗正逐渐成为 PAH 治疗的标准疗法，推动市场成长和创新。例如，2024 年 3 月，强生公司的 OPSYNVI®（Macitentan和他达拉非）成为首个获得美国 FDA核准的用于治疗成人肺动脉高压 (PAH) 的每日一次单片复方製剂。该核准基于 III 期 A 类药物评估试验 (DUE) 的成功，该试验证实了肺血流动力学的显着改善。 OPSYNVI(R) 将两种成熟的治疗方法结合到一片药片中，符合建议早期联合治疗的临床指引。

人们越来越重视创新治疗方法。

随着人们对肺动脉高压 (PAH) 创新治疗方法的兴趣日益浓厚，旨在解决该疾病根本原因的基因疗法和生物目标的研究正在取得进展。基因疗法有望改变 PAH 相关的遗传因素，从而提供超越单纯症状管理的长期解决方案。另一方面，生物目标则专注于导致疾病进展的特定分子通路，从而实现更个人化和有效的治疗。这些新方法代表了缓解疾病的突破，并有望提高 PAH 患者的存活率和整体生活品质。因此，Liquidia 公司的 YUTREPIA™（曲前列尼尔）吸入粉剂于 2024 年 8 月获得美国食品药物管理局 (FDA) 的临时批准，用于治疗成人肺动脉高压 (PAH) 和伴有间质性肺病 (ILD) 的肺动脉高压 (PH-ILD) 患者。此次核准是基于食品药物管理局 III 期临床试验，该试验证实了 YUTREPIA 的安全性和有效性。该公司计划尽快寻求最终核准，以满足 PAH 和 PH-ILD 患者未被满足的医疗需求。

以病人为中心的照护和数位健康

以患者为中心的护理措施和数位健康工具的整合正在透过提高治疗依从性和疗效，影响肺动脉高压 (PAH) 治疗市场的动态。行动应用程式和穿戴式装置等数位健康工具能够持续监测心率和血氧饱和度等生命征象。此外，数位平台促进了患者与医疗团队之间的顺畅沟通，从而改善了疾病的整体管理。这种整合不仅改善了患者的治疗效果，还使患者能够在自身的 PAH 管理中发挥积极作用，从而提高生活品质并提升医疗服务的效率。此外，2024 年发表在《美国医学传播杂誌》(AJMC) 上的报导指出，孪生技术有望彻底改变肺动脉高压 (PH) 的治疗方式。该技术透过创建患者的虚拟模型来模拟疾病进展并预测治疗结果。这项研究凸显了个人化医疗和In Silico临床试验的潜力，它们可以减少传统临床试验所需的时间和成本。数位健康和​​孪生技术的这些进步正在改善肺动脉高压治疗市场的前景，推动市场成长，并有助于改善患者照护。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：肺动脉高压（PAH）治疗的全球市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依药物类别划分

  • 内皮素受体拮抗剂（ERA）
  • 血管扩张剂
  • 磷酸二酯酶 5 (PDE-5) 抑制剂
  • 可溶性鸟苷酸环化酶（sGC）刺激剂
  • 钙离子通道阻断剂（CCBs）
  • 前列腺环素和前列腺环素类似物
  • 其他的

第七章 市场区隔：依给药途径

  • 吸入
  • 注射药物
  • 口服

第八章 市场区隔：依最终用户划分

  • 医院
  • 诊所
  • 其他的

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Actelion Pharmaceuticals Ltd（Johnson & Johnson）
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
Product Code: SR112026A2399

The global pulmonary arterial hypertension (PAH) drugs market size reached USD 8.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 12.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.05% during 2026-2034. The market is experiencing significant growth mainly driven by advancements in targeted therapies, increasing prevalence of PAH and growing awareness. Expanding research and development (R&D) efforts are also creating a positive outlook for the market further across the world.

PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET ANALYSIS:

  • Major Market Drivers: Key market drivers include the rising prevalence of PAH due to genetic factors and associated conditions such as cardiovascular diseases and HIV. Advancements in treatment options including novel therapies like endothelin receptor antagonists and prostacyclin analogs are boosting demand. An increased awareness among healthcare professionals and patients about early diagnosis and treatment also supports market growth. Moreover, supportive government initiatives and favorable reimbursement policies are encouraging greater accessibility to PAH medications. Ongoing research and development (R&D) to discover more effective therapies further drives the market growth, enhancing treatment options for patients worldwide.
  • Key Market Trends: Key market trends include a growing focus on combination therapies which offer enhanced efficacy by targeting multiple pathways involved in PAH. The rise of precision medicine is also influencing the market growth as personalized treatments are increasingly tailored to individual patient needs. There is also a noticeable shift toward oral and inhaled formulations, providing more convenience and better patient adherence as compared to intravenous options. Additionally, biotech companies are investing heavily in gene and cell-based therapies, which have the potential to revolutionize PAH treatment.
  • Geographical Trends: Geographical trends in market shows significant growth in North America, due to its advanced healthcare infrastructure, strong R&D investment, and higher PAH prevalence. Europe follows closely, with countries like Germany and the United Kingdom contributing through increased awareness and availability of advanced treatments. The Asia-Pacific region is experiencing rapid growth due to rising healthcare expenditure, improving diagnostic facilities, and growing awareness about PAH. In countries like China and India, expanding patient population base and increasing access to healthcare are fueling the demand for PAH drugs.
  • Competitive Landscape: Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation, among many others.
  • Challenges and Opportunities: The market faces various challenges including high treatment costs which can limit access especially in developing regions. The complexity of PAH as a disease, with its multiple pathways, also makes treatment development difficult. Limited awareness in certain regions further hampers early diagnosis and intervention. However, opportunities are emerging through advancements in gene and cell-based therapies, which have the potential to offer more effective treatments. Increased focus on combination therapies presents another growth avenue, improving patient outcomes. In line with this, improving healthcare access in developing regions offers significant market potential for PAH drug manufacturers.

PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET TRENDS:

Increased Use of Combination Therapies

Physicians are increasingly adopting combination therapies to enhance treatment efficacy in Pulmonary Arterial Hypertension (PAH). By prescribing a mix of drugs from different therapeutic classes, they target multiple biological pathways involved in PAH. This multifaceted approach helps to manage symptoms, slow disease progression, and improve overall patient outcomes more effectively. Additionally, combination therapies can allow for lower doses of individual medications, potentially reducing side effects and enhancing patient adherence. As clinical evidence supports their benefits, combination treatments are becoming the standard of care in PAH management, driving market growth and innovation. For instance, in March 2024, Johnson & Johnson's OPSYNVI(R) (macitentan and tadalafil) was approved by the U.S. FDA as the first once-daily single-tablet combination therapy for adults with pulmonary arterial hypertension (PAH). This approval is based on the successful Phase 3 A DUE study, which showed significant pulmonary hemodynamic improvement. OPSYNVI(R) combines two established treatments into a single tablet, aligning with clinical guideline recommendations for early combination therapy.

Rising Focus on Innovative Therapies

The rising focus on innovative therapies in Pulmonary Arterial Hypertension (PAH) is driving the exploration of gene therapies and targeted biologics, which aim to address the root causes of the disease. Gene therapies hold the potential to modify genetic factors involved in PAH, offering a long-term solution rather than just symptom management. Targeted biologics, on the other hand, focus on specific molecular pathways contributing to disease progression, allowing for more personalized and effective treatments. These novel approaches could lead to significant breakthroughs in disease modification, improving survival rates and overall quality of life for PAH patients. In line with this, in August 2024, Liquidia Corporation's YUTREPIA(TM) (treprostinil) inhalation powder received tentative approval from the U.S. FDA to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is based on the Phase 3 INSPIRE trial, which demonstrated the safety and efficacy of YUTREPIA. The company plans to seek final approval at the earliest to address the unmet needs of PAH and PH-ILD patients.

Patient-Centered Care and Digital Health

Patient-centered care initiatives and the integration of digital health tools are influencing the pulmonary arterial hypertension drugs market dynamics by enhancing treatment adherence and outcomes. Digital health tools, including mobile apps and wearable devices, enable continuous monitoring of vital signs such as heart rate and oxygen levels. Additionally, digital platforms facilitate seamless communication between patients and medical teams, enhancing overall disease management. This integration not only improves patient outcomes but also empowers individuals to take an active role in managing their PAH, leading to increased quality of life and more efficient healthcare delivery. Moreover, in an article published by AJMC in 2024, it was suggested that twin technology has the potential to revolutionize pulmonary hypertension (PH) treatment. This technology involves creating virtual models of patients to simulate disease progression and predict treatment outcomes. The study emphasizes the potential for personalized care and in silico clinical trials, which could reduce the time and costs associated with traditional trials. These advancements in digital health and twin technology are creating a positive pulmonary arterial hypertension drugs market outlook, driving growth and improving patient care.

PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET SEGMENTATION:

Breakup by Drug Class:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Prostacyclin and Prostacyclin Analogs accounts for the majority of the market share

Prostacyclin and prostacyclin analogs dominate the pulmonary arterial hypertension (PAH) drugs market, accounting for the largest market share due to their critical role in managing the disease. These medications work by dilating blood vessels, reducing vascular resistance, and inhibiting platelet aggregation, which effectively lowers blood pressure in the pulmonary arteries. Their proven efficacy in improving exercise capacity and delaying disease progression makes them a cornerstone of PAH therapy. Additionally, the availability of various administration forms, such as intravenous, subcutaneous, and inhaled options, enhances their accessibility and convenience for patients. Ongoing advancements and the introduction of newer analogs further solidify their leading position, driving sustained pulmonary arterial hypertension drugs market growth .

Breakup by Route of Administration:

  • Inhalation
  • Injectable
  • Oral Administration

Oral Administration holds the largest share of the industry

Oral administration holds the largest share of the pulmonary arterial hypertension (PAH) drugs market due to its significant advantages in patient convenience and adherence. Oral medications are easy to administer, non-invasive, and can be taken at home without the need for specialized medical facilities, making them highly attractive for long-term treatment. This ease of use enhances patient compliance, which is crucial for managing a chronic condition like PAH. Additionally, advancements in pharmaceutical formulations have improved the efficacy and safety profiles of oral PAH drugs, thereby reducing side effects and increasing their appeal. For instance, in December 2023, Granules obtained approval from the U.S. Food and Drug Administration for its generic version of Viatris Specialty's Revatio, a treatment for pulmonary arterial hypertension (PAH). The product is bioequivalent and therapeutically equivalent to Viatris's Sildenafil for oral suspension, 10 mg/ml. Granules stated that the drug is intended to enhance exercise ability and delay clinical worsening in PAH patients.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals are a primary end user in the Pulmonary Arterial Hypertension (PAH) drugs market, playing a crucial role in diagnosis, treatment, and ongoing management of the condition. Equipped with advanced diagnostic tools and specialized cardiology and pulmonology departments, hospitals facilitate the accurate identification of PAH, enabling timely and effective intervention. They administer a wide range of PAH medications, including advanced biologics and combination therapies, ensuring comprehensive patient care. Additionally, hospitals often participate in clinical trials and research initiatives, driving innovation and the development of new treatments. The centralized infrastructure and multidisciplinary approach in hospitals significantly contribute to the growth and adoption of PAH drugs in the market.

Clinics are essential end users in the Pulmonary Arterial Hypertension (PAH) drugs market, providing accessible and continuous care for patients with PAH. These outpatient facilities offer routine monitoring, medication management, and personalized treatment plans, enhancing patient adherence and outcomes. Clinics often collaborate with specialists to deliver comprehensive care, utilizing a variety of PAH drugs, including oral therapies and injectable medications. The convenience and localized presence of clinics make them pivotal in managing chronic conditions like PAH, ensuring that patients receive timely adjustments to their treatment regimens. Additionally, clinics contribute to market growth by increasing the distribution channels for PAH medications and fostering patient education and support initiatives.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest pulmonary arterial hypertension drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pulmonary arterial hypertension (PAH) drugs.

North America leads the Pulmonary Arterial Hypertension (PAH) drugs market, accounting for the largest market share due to several key factors. The region benefits from a highly advanced healthcare infrastructure and widespread access to specialized medical facilities, enabling effective diagnosis and treatment of PAH. According to pulmonary arterial hypertension drugs market overview, the rising prevalence of cardiovascular and respiratory diseases drives the demand for PAH medications across the region. Additionally, North America is home to major pharmaceutical companies that invest heavily in research and development (R&D), fostering innovation and the introduction of new therapies. Favorable regulatory frameworks and substantial healthcare funding further support market growth. Moreover, increased awareness and education about PAH contribute to the early detection and higher treatment rates, solidifying North America's dominant market position. For instance, in September 2023, researchers at Vanderbilt University developed a new drug, VU6047534, to treat pulmonary arterial hypertension without serious neurological side effects. The drug targets serotonin 2B receptors in the heart and lungs, promoting organ healing and potentially reversing damage from heart attacks. The compound, designed to stay out of the brain, represents a promising therapy for PAH. The research was funded by the National Institutes of Health and Vanderbilt University.

COMPETITIVE LANDSCAPE:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation. ()
  • The Pulmonary Arterial Hypertension (PAH) drugs market is highly competitive, with numerous pharmaceutical companies vying for market share through the development of innovative therapies. The market is characterized by a growing focus on advanced treatments, such as combination therapies and targeted biologics, which offer improved efficacy and patient outcomes. Companies are investing heavily in research and development to introduce novel drugs and enhance existing treatments. Pricing strategies, regulatory approvals, and patent expirations significantly influence market dynamics. Additionally, the increasing availability of generics intensifies competition, while market leaders leverage strong distribution networks and clinical trial results to maintain their positions.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2025?

2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2026-2034?

3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?

4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?

5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?

6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?

7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?

8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2025
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2025
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players